2025-12-17 - Analysis Report
Okay, let's break down the analysis of Johnson & Johnson (JNJ) based on the provided data.

**1) Return Rate Comparison (vs. S&P 500)**

*   **Overview:** Johnson & Johnson (JNJ) is a global healthcare company focused on pharmaceuticals, medical devices, and consumer health products.
*   **JNJ Cumulative Return:** 61.30%
*   **VOO (S&P 500) Cumulative Return:** 99.81%
*   **Divergence:** -42.6 (Current), Relative Divergence: 27.9

**Analysis:**

*   JNJ has significantly underperformed the S&P 500 over the analyzed period.
*   The divergence of -42.6 indicates a substantial difference in cumulative return. JNJ has generated 42.6% less in cumulative return than VOO (S&P 500).
*   The relative divergence of 27.9 suggests that the current divergence is relatively close to the minimum divergence experienced between the two equities (not good).

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 336.6 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 310.9 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 351.4 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 379.2 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 412.2 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 425.6 |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3 | 377.6 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 348.4 |
| 2023-2025  | 32.0% | 79.6% | -32.0% | 0.1 | 504.3 |

**Analysis:**

*   **CAGR:** Fluctuates significantly, showing periods of growth and decline. Recent years (2021-2025) show volatility.
*   **MDD:** High Maximum Drawdown (MDD) figures, especially in recent periods, indicate substantial risk and potential for loss.
*   **Alpha:** Primarily negative Alpha indicates underperformance relative to the benchmark, except for the 2020-2022 period. This suggests that JNJ has not consistently generated excess returns compared to its expected performance based on its beta.
*   **Beta:** Beta values are generally low, suggesting lower volatility compared to the market. A beta near 0.3 indicates that JNJ's price moves only 30% as much as the overall market. The low volatility has failed to provide comparable returns.
*   **Cap:** The large Cap values demonstrate JNJ is a Mega Cap company.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 209.30
*   **Previous Close:** 214.17
*   **Change:** -2.27
*   **5-day SMA:** 210.32
*   **20-day SMA:** 205.49
*   **60-day SMA:** 194.26

**Analysis:**

*   The stock price is currently trending downward, closing lower than its previous close and below the 5-day moving average.
*   The 5-day SMA is above the 20-day SMA, but the 20-day SMA is above the 60-day SMA, suggesting a short-term rebound may be occurring after a period of longer-term upward movement.

**3) RSI, PPO and other indicators**

*   **MRI:** 0.7 (Medium Investment Recommended)
*   **RSI:** 54.23 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.1071 (Slightly positive - indicates a slightly bullish trend)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (Safe - MRI:0.80)
*   **Recent (20 days) relative divergence change:** -0.2 (Negative - Short-term decline)
*   **Expected Return (%):** -60.6% (Significant underperformance compared to S&P 500 if invested long-term)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI indicates a neutral condition, meaning the stock is neither overbought nor oversold.
*   The PPO suggests a very slight bullish trend.
*   The hybrid signal recommends buying into the stock.
*   The negative divergence change suggests a recent decline in performance relative to its comparison.
*   The extremely negative expected return indicates a very poor outlook for future investment, underperforming the S\&P 500.

**4) Recent News & Significant Events:**

*   **FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook:** These factors could be influencing investor sentiment. The talc verdicts have been a long-standing overhang for JNJ.
*   **$JNJ stock is down 3% today:** Indicates recent negative price movement.
*   **Exploring Valuation Perspectives After Recent Share Price Momentum:** Suggests recent volatility and uncertainty in the stock's valuation.
*   **Institutional Investors Are Raising Their Stakes:** This could be a positive sign, suggesting confidence from larger investors.
*   **Gradient Investments LLC Purchases Shares:** Another sign of institutional confidence.
*   **Johnson & Johnson Stock Surged 40%, Here's Why:** This article requires more context. A 40% surge is significant, but it's crucial to understand the time frame and drivers behind it.

**Analysis:**

The news is mixed. While some institutional investors are buying, recent negative price movements and ongoing legal issues surrounding talc powder are weighing on the stock. It is important to note that a 40% surge is mentioned in the news headlines. This large surge is at odds with the expected return calculated earlier.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price (avg/high/low):** 207.75 / 240.00 / 155.00

**Analysis:**

*   Analysts have a generally positive outlook on JNJ with a consensus rating of "Buy".
*   The average target price is slightly below the current price.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

**Analysis:**

*   Revenue is relatively stable, with a slight increase in recent quarters.
*   EPS is volatile, and there is a repeat of data in the final row.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30 | $23.99B | 69.56%        |
| 2025-06-30 | $23.74B | 67.87%        |
| 2025-03-31 | $21.89B | 66.40%        |
| 2024-12-31 | $22.52B | 68.35%        |
| 2024-09-30 | $22.47B | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-09-30 | $79.28B   | 6.50%  |
| 2025-06-30 | $78.47B   | 7.06%  |
| 2025-03-31 | $78.11B   | 14.08% |
| 2024-12-31 | $71.49B   | 4.80%  |
| 2024-09-30 | $70.16B   | 3.84%  |

**Analysis:**

*   **Revenue:** Shows a generally increasing trend.
*   **Profit Margin:** Consistently high, indicating strong profitability.
*   **Equity:** Growing, reflecting the company's financial health.
*   **ROE:** Fluctuates, with a significant peak in 2025-03-31.

**7) Comprehensive Analysis (Summary)**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 in terms of cumulative return.
*   **Mixed Signals:** Technical indicators provide mixed signals. MRI says medium, RSI is neutral, PPO is slightly positive, divergence is down, and expected returns are very poor.
*   **Analyst Optimism vs. Data:** Analysts have a generally positive outlook (Buy rating), but this contrasts with some negative trends in the data, particularly the large negative expected return and recent price declines.
*   **Legal and Market Uncertainty:** Ongoing legal battles related to talc powder continue to create uncertainty. This is in addition to the recent price decline.
*   **Financial Strength:** JNJ demonstrates solid financial health with high profit margins and growing equity. This may explain the current investment recommendation from the hybrid signal and the ratings of the analysts.

**Overall Recommendation:**

Based on the comprehensive analysis, a cautious approach to JNJ is warranted. While the company exhibits financial strength and analysts have a positive outlook, the recent underperformance, legal uncertainties, and mixed technical signals suggest potential risks. Investors should carefully weigh these factors and consider their own risk tolerance before making any investment decisions. The 40% surge mentioned in the news may be worth investigating if the news is reliable.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.